MK‑677 (Ibutamoren)
Experimental growth-hormone-boosting compound taken by mouth (not a SARM); it worsened blood sugar in a human trial.
The links above are labelled third-party affiliate links. MolekulaX does not sell and does not verify product quality.

DETAILED OVERVIEW
What is MK-677 (Ibutamoren)?
MK-677 (ibutamoren) is an experimental compound that, taken by mouth, increases the release of growth hormone and thereby the level of IGF-1 (a substance that carries out the effects of growth hormone). It has never been approved as a medicine, and its clinical development was halted. It is not a SARM: it does not act on the receptor for male hormones and does not suppress the body's own testosterone production.
In a two-year placebo-controlled trial in older adults, growth hormone and IGF-1 returned to the range typical of young adults, and fat-free body mass rose by about 1.1 kg. Meanwhile carbohydrate metabolism got worse: fasting blood sugar and insulin resistance increased, and this did not settle during the trial. It causes a strong increase in appetite, and water retention and numb hands can also occur. It is contraindicated in diabetes, prediabetes and heart failure, and it must not be used in pregnancy. It is banned in competitive sport all year round.
Mechanism
Ghrelin (hunger hormone) receptor stimulator; more growth hormone, IGF-1
Body composition (Nass 2008)
In older adults, fat-free body mass rose by about 1.1 kg
Critical adverse effect
Worsening insulin sensitivity and rising fasting glucose that did not resolve during the trial.
Half-life
~4-6 h, but the IGF-1 elevation is sustained, so once-daily dosing suffices.
Legal status
Never approved. WADA-banned (S2, GH secretagogues).
No anecdote collected yet.
Data console
Lab data
Nass R, Pezzoli SS, Oliveri MC . Effects of an oral ghrelin mimetic on body composition and clinical outcomes in healthy older adults: a randomized trial.. Annals of internal medicine.
Murphy MG, Plunkett LM, Gertz BJ . MK-677, an orally active growth hormone secretagogue, reverses diet-induced catabolism.. The Journal of clinical endocrinology and metabolism.
Murphy MG, Bach MA, Plotkin D . Oral administration of the growth hormone secretagogue MK-677 increases markers of bone turnover in healthy and functionally impaired elderly adults. The MK-677 Study Group.. Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.
Sevigny JJ, Ryan JM, van Dyck CH . Growth hormone secretagogue MK-677: no clinical effect on AD progression in a randomized trial.. Neurology.
Safety
Side effects, stop signs, contraindications
Side effects · 6
- Marked appetite increase: the direct, expected consequence of ghrelin receptor agonism. For many this is the strongest noticeable effect, and a serious drawback during a cutting phase.
- Worsening insulin sensitivity and rising fasting glucose: in the two-year Nass 2008 trial this was the most significant metabolic adverse effect, and it did not resolve during treatment.
- Water retention and peripheral edema: a classic accompaniment of GH axis activation, typically most pronounced in the first weeks.
- Carpal-tunnel-like complaints: numbness and paraesthesia in the hand from soft-tissue swelling, usually easing on dose reduction.
- Lethargy and daytime drowsiness, especially in the introductory phase; many therefore switch to evening dosing.
- Mild prolactin and cortisol elevation: usually clinically insignificant, but worth measuring if symptoms appear.
Contraindications · 5
- Diabetes, prediabetes or insulin resistance: MK-677 documentedly worsens glucose metabolism, an absolute contraindication.
- Active or treated malignancy: elevated IGF-1 carries a theoretical proliferative risk, avoid without oncology consultation.
- Heart failure or untreated hypertension: fluid retention places further load on the circulation.
- Pregnancy and breastfeeding: no safety data, use is prohibited.
- Competitive sport under testing: WADA bans GH secretagogues (S2), with the same sanction as growth hormone itself.
Related Performance Compounds
Same therapeutic category
Studies
Related research and clinical findings
Effects of an oral ghrelin mimetic on body composition and clinical outcomes in healthy older adults: a randomized trial.
Nass R, Pezzoli SS, Oliveri MC
MK-677, an orally active growth hormone secretagogue, reverses diet-induced catabolism.
Murphy MG, Plunkett LM, Gertz BJ
Oral administration of the growth hormone secretagogue MK-677 increases markers of bone turnover in healthy and functionally impaired elderly adults. The MK-677 Study Group.
Murphy MG, Bach MA, Plotkin D
Growth hormone secretagogue MK-677: no clinical effect on AD progression in a randomized trial.
Sevigny JJ, Ryan JM, van Dyck CH
Telegram
Have a question about MK‑677 (Ibutamoren)?
Reach out to an advisor on Telegram. Performance compounds are presented with a harm-reduction approach, based on peer-reviewed evidence.
Personalized consultation
Want a detailed conversation tailored to your data?
Fill out the prep intake form (your goals, training and health data), and the advisor prepares from it to give genuinely personalized guidance.
Fill out the form~5–7 min · prep questionnaire · confidential · GDPR-compliant
The information here is for educational and scientific purposes only. Performance-enhancing compounds (AAS, prohormones, stimulants, doping agents) are illegal without prescription in Hungary and most of the EU, and carry serious health and legal risks. WADA bans them in competitive sport. This is NOT a usage guide, and we do not encourage any illegal use. If you do use them, medical supervision and regular bloodwork are ESSENTIAL. Severe endocrine, cardiovascular, hepatic and psychiatric side effects are possible.
